Patents by Inventor Klaus-Peter Koller

Klaus-Peter Koller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8574909
    Abstract: The invention relates to a strain of the yeast Saccharomyces cerevisiae which, owing to deletion of the genomic sequences, no longer synthesizes hexose transporters and, as a consequence, can no longer grow on substrates with hexoses as the only carbon source, and whose ability of growing on a substrate with a hexose as the only carbon source is restored when it expresses a GLUT4 gene.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: November 5, 2013
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Guenter Mueller, Klaus-Peter Koller, Eckhard Boles, Roman Niedbal, Silke Dlugai
  • Publication number: 20060275319
    Abstract: The invention relates to a strain of the yeast Saccharomyces cerevisiae which, owing to deletion of the genomic sequences, no longer synthesizes hexose transporters and, as a consequence, can no longer grow on substrates with hexoses as the only carbon source, and whose ability of growing on a substrate with a hexose as the only carbon source is restored when it expresses a GLUT4 gene.
    Type: Application
    Filed: April 7, 2006
    Publication date: December 7, 2006
    Applicant: sanofi-aventis Deutschland GmbH
    Inventors: Gunter Muller, Klaus-Peter Koller, Eckhard Boles, Roman Wieczorke, Silke Dlugai
  • Patent number: 7052900
    Abstract: The invention relates to a strain of the yeast Saccharomyces cerevisiae which, owing to deletion of the genomic sequences, no longer synthesizes hexose transporters and, as a consequence, can no longer grow on substrates with hexoses as the only carbon source, and whose ability of growing on a substrate with a hexose as the only carbon source is restored when it expresses a GLUT4 gene.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: May 30, 2006
    Assignee: sanofi-aventis Pharma Deutschland GmbH
    Inventors: Gunter Muller, Klaus-Peter Koller, Eckhard Boles, Roman Wieczorke, Silke Dlugai
  • Patent number: 6649369
    Abstract: The present invention relates to a process for delaying the deactivation of glutaryl amidase during enzyme catalysis. The enzyme catalyst is, after maximum conversion of the substrate, separated off by filtration and can be reused in a subsequent reaction batch. In each reaction cycle, the enzyme catalyst loses activity. The inactivation of the enzyme catalyst can be delayed by bringing it into contact with a thiol during the reaction.
    Type: Grant
    Filed: April 9, 2002
    Date of Patent: November 18, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Jürgen Bongs, Johannes Meiwes, Wolfgang Kruse, Klaus-Peter Koller
  • Publication number: 20030166258
    Abstract: The invention relates to a strain of the yeast Saccharomyces cerevisiae which, owing to deletion of the genomic sequences, no longer synthesizes hexose transporters and, as a consequence, can no longer grow on substrates with hexoses as the only carbon source, and whose ability of growing on a substrate with a hexose as the only carbon source is restored when it expresses a GLUT4 gene.
    Type: Application
    Filed: February 5, 2002
    Publication date: September 4, 2003
    Inventors: Gunter Muller, Klaus-Peter Koller, Eckhard Boles, Roman Wieczorke, Silke Dlugai
  • Publication number: 20030082634
    Abstract: The invention relates to the cell regulation factor TTO 20, DNA coding therefor, its preparation and use, antibodies binding to TTO 20 and the use of DNA coding for TTO 20 and an antibody binding to TTO 20 for use in a diagnostic kit for the detection of inflammatory disorders, in particular rheumatoid arthritis.
    Type: Application
    Filed: September 10, 2002
    Publication date: May 1, 2003
    Applicant: Aventis Pharma Deutschland GmbH
    Inventor: Klaus-Peter Koller
  • Publication number: 20020155566
    Abstract: The present invention relates to a process for delaying the deactivation of glutaryl amidase during enzyme catalysis. The enzyme catalyst is, after maximum conversion of the substrate, separated off by filtration and can be reused in a subsequent reaction batch. In each reaction cycle, the enzyme catalyst loses activity. The inactivation of the enzyme catalyst can be delayed by bringing it into contact with a thiol during the reaction.
    Type: Application
    Filed: April 9, 2002
    Publication date: October 24, 2002
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Jurgen Bongs, Johannes Meiwes, Wolfgang Kruse, Klaus-Peter Koller
  • Patent number: 6468750
    Abstract: The invention relates to the cell regulation factor TTO 20, DNA coding therefor, its preparation and use, antibodies binding to TTO 20 and the use of DNA coding for TTO 20 and an antibody binding to TTO 20 for use in a diagnostic kit for the detection of inflammatory disorders, in particular rheumatoid arthritis.
    Type: Grant
    Filed: May 2, 2000
    Date of Patent: October 22, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventor: Klaus-Peter Koller
  • Patent number: 6395507
    Abstract: A process is provided for delaying the deactivation of glutaryl amidase during catalysis. The amidase is, after maximum conversion of a substrate, separated off by filtration and can be reused in a subsequent reaction batch. In each reaction cycle, the amidase loses activity. The inactivation of the amidase can be delayed by bringing it into contact with a thiol during the reaction. The thiol is preferably 2-mercaptoethanol or cysteine.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: May 28, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Jürgen Bongs, Johannes Meiwes, Wolfgang Kruse, Klaus-Peter Koller
  • Patent number: 5830743
    Abstract: The gene encoding glutarylacylase (GA) contained in the plasmid pCM 145 (DSM 6409) permits the expression of GA in E. coli in high yields.
    Type: Grant
    Filed: September 28, 1994
    Date of Patent: November 3, 1998
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Klaus-Peter Koller, Gunther Johannes Riess, Werner Aretz
  • Patent number: 5766881
    Abstract: Improved, induction-free process for the recombinant preparation of glutarylamidase. The invention relates to a recombinant process for preparing glutarylamidase (GA), wherein the GA gene is expressed constitutively from an expression vector. In certain embodiments, the promoter for constitutively expressing the GA gene is a trc promoter or a trc-equivalent promoter which does not have any repressor or has a non-functional repressor.
    Type: Grant
    Filed: October 17, 1995
    Date of Patent: June 16, 1998
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Werner Aretz, Ulrich Holst, Klaus Peter Koller
  • Patent number: 5728543
    Abstract: A process is described to specifically hydrolyze the amino acid chain of preproinsulin analogs to give the corresponding insulins. The hydrolysis is catalyzed by clostripain and, if necessary, carboxypeptidase B.
    Type: Grant
    Filed: August 8, 1994
    Date of Patent: March 17, 1998
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Michael Dorschug, Klaus-Peter Koller, Rudiger Marquardt, Johannes Meiwes
  • Patent number: 5667991
    Abstract: The present invention refers in particular to the structural gene sequence of the peptide antibiotic mersacidin. Sequencing revealed that premersacidin consists of an unusually long 48 amino acid leader sequence and a 20 amino acid propeptide part (Seq. ID No:1) which is modified during biosynthesis to the mature lantibiotic.
    Type: Grant
    Filed: September 8, 1995
    Date of Patent: September 16, 1997
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Klaus-Peter Koller, Hans Georg Sahl, Gabriele Bierbaum
  • Patent number: 5426036
    Abstract: The tendamistat gene can be used for the construction of fused genes with which fusion proteins are expressed and excreted in Streptomycetes host cells. The tendamistat portion can be modified, in particular it can be C-terminal shortened. When a gene for a shortened proinsulin in which the insulin B chain is linked to the A chain only via Lys or Lys-Lys is coupled to the tendamistat gene, this gene construction is introduced into an expression vector, and the latter is used to transform a Streptomycetes host cell, there is expression and secretion of the corresponding fusion protein. The fusion protein can easily be cleaved to give insulin precursors because of correctly established disulfide bonds. Genetic structures which code for the signal sequence and about the first ten amino acids of tendamistat as well as a desired protein are expressed in streptomyces host cells with a high yield, and the fusion proteins are secreted into the medium.
    Type: Grant
    Filed: March 12, 1993
    Date of Patent: June 20, 1995
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Klaus-Peter Koller, Gunther Riess, Eugen Uhlmann, Holger Wallmeier
  • Patent number: 4918007
    Abstract: A tandem arrangement of two promoters which are each active in Streptomyces is provided. The tandem arrangement provides a considerable increase in protein expression.
    Type: Grant
    Filed: October 8, 1986
    Date of Patent: April 17, 1990
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Klaus-Peter Koller, Gunther J. Riess
  • Patent number: 4770861
    Abstract: Cesium chloride is recovered from used density gradient solutions by extraction of lipophilic and coloring components using a lipophilic solvent, subsequent extraction with a polar protic organic solvent, adding perchlorate ions to the extraction residue, and converting the precipitated cesium perchlorate into cesium chloride.
    Type: Grant
    Filed: February 10, 1987
    Date of Patent: September 13, 1988
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Klaus-Peter Koller, Wilfried Schwab